23rd Aug 2017 07:00
Silence to host Capital Markets event on 14 November 2017
23 August 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the Company will host a Capital Markets event for investors, analysts and media at ME London Hotel, Strand, London WC2R 1HA on Tuesday 14 November between 3:00pm and 5:30pm GMT.
At the meeting, Silence will provide an update on its RNAi pipeline and proprietary technology platforms, as well as a review of the Company's strategy. Further details will follow in due course.
To register your interest, please contact [email protected].
Enquiries:
Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer David Ellam, Chief Financial Officer | Tel: +44 (0)20 3457 6900 |
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/Oliver Jackson
| Tel: +44 (0)20 7418 8900 |
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert
| Tel: +44 (0) 20 3727 1000 |
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.
Related Shares:
SLN.L